# Harald Hampel

List of Publications by Year
in descending order

| 471 papers | 68,835 citations | 1231<br>110<br>h-index | 849<br>244<br>g-index |
|---|---|---|---|
| 550<br>all docs | 550<br>docs citations | 550<br>times ranked | 49984<br>citing authors |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1 | Inflammation and Alzheimer's disease. Neurobiology of Aging, 2000, 21, 383-421. | 1.5 | 4,069 |
| 2 | Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458. | 9.4 | 3,741 |
| 3 | Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093. | 9.4 | 2,697 |
| 4 | Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629. | 4.9 | 2,657 |
| 5 | Mild cognitive impairment. Lancet, The, 2006, 367, 1262-1270. | 6.3 | 2,401 |
| 6 | Variant of<i>TREM2</i>Associated with the Risk of Alzheimer's Disease. New England Journal of Medicine, 2013, 368, 107-116. | 13.9 | 2,085 |
| 7 | Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430. | 9.4 | 1,962 |
| 8 | Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435. | 9.4 | 1,708 |
| 9 | Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 131-144. | 4.9 | 1,598 |
| 10 | Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323. | 0.4 | 1,318 |
| 11 | A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547. | 1.5 | 1,216 |
| 12 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924. | 3.8 | 1,166 |
| 13 | CSF markers for incipient Alzheimer's disease. Lancet Neurology, The, 2003, 2, 605-613. | 4.9 | 1,156 |
| 14 | CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385. | 3.8 | 1,009 |
| 15 | The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain, 2018, 141, 1917-1933. | 3.7 | 1,008 |
| 16 | Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384. | 9.4 | 783 |
| 17 | New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436. | 9.4 | 700 |
| 18 | Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. NeuroImage, 2005, 28, 980-995. | 2.1 | 637 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 19 | Sex differences in Alzheimer disease â€" the gateway to precision medicine. Nature Reviews Neurology, 2018, 14, 457-469. | 4.9 | 573 |
| 20 | Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Reviews Drug Discovery, 2010, 9, 560-574. | 21.5 | 560 |
| 21 | Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology, The, 2009, 8, 619-627. | 4.9 | 542 |
| 22 | CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain, 2006, 129, 3035-3041. | 3.7 | 541 |
| 23 | The Amyloid-Î² Pathway in Alzheimerâ€™s Disease. Molecular Psychiatry, 2021, 26, 5481-5503. | 4.1 | 478 |
| 24 | Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, 38-48. | 0.4 | 447 |
| 25 | Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 2018, 14, 639-652. | 4.9 | 434 |
| 26 | Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease. Archives of General Psychiatry, 2004, 61, 95. | 13.8 | 390 |
| 27 | Focal Decline of Cortical Thickness in Alzheimer's Disease Identified by Computational Neuroanatomy. Cerebral Cortex, 2005, 15, 995-1001. | 1.6 | 390 |
| 28 | Implementation of subjective cognitive decline criteria in research studies. Alzheimer's and Dementia, 2017, 13, 296-311. | 0.4 | 375 |
| 29 | Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853. | 3.9 | 370 |
| 30 | Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia, 2001, 35, 72-79. | 2.5 | 358 |
| 31 | The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386. | 0.4 | 354 |
| 32 | Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 58-69. | 0.4 | 352 |
| 33 | Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950. | 1.1 | 347 |
| 34 | Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiology of Aging, 2012, 33, 1203-1214.e2. | 1.5 | 346 |
| 35 | CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261. | 0.4 | 344 |
| 36 | The Î²-Secretase BACE1 in Alzheimerâ€™s Disease. Biological Psychiatry, 2021, 89, 745-756. | 0.7 | 336 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 37 | Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Experimental Gerontology, 2010, 45, 30-40. | 1.2 | 330 |
| 38 | Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends in Neurosciences, 2011, 34, 430-442. | 4.2 | 309 |
| 39 | Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. NeuroImage, 2010, 50, 162-174. | 2.1 | 287 |
| 40 | Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338. | 3.7 | 284 |
| 41 | Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nature Genetics, 2015, 47, 445-447. | 9.4 | 283 |
| 42 | Value of CSF Î²-amyloid1â€"42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry, 2004, 9, 705-710. | 4.1 | 280 |
| 43 | Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430. | 0.6 | 280 |
| 44 | Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Research, 1999, 88, 163-171. | 1.7 | 274 |
| 45 | A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117. | 4.1 | 260 |
| 46 | Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231. Archives of Neurology, 2002, 59, 1267. | 4.9 | 256 |
| 47 | Lithium Trial in Alzheimer's Disease. Journal of Clinical Psychiatry, 2009, 70, 922-931. | 1.1 | 252 |
| 48 | The future of blood-based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 115-131. | 0.4 | 250 |
| 49 | Biological markers for therapeutic trials in Alzheimer's disease. Neurobiology of Aging, 2003, 24, 521-536. | 1.5 | 249 |
| 50 | The cerebrospinal fluid "Alzheimer profile" Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713. | 0.4 | 249 |
| 51 | Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiology of Aging, 2008, 29, 23-30. | 1.5 | 242 |
| 52 | IFATS Collection: The Conditioned Media of Adipose Stromal Cells Protect Against Hypoxia-Ischemia-Induced Brain Damage in Neonatal Rats. Stem Cells, 2009, 27, 478-488. | 1.4 | 238 |
| 53 | Amyloid Î² peptide ratio 42/40 but not AÎ²42 correlates with phospho-Tau in patients with low-and high-CSF AÎ²40 load. Journal of Neurochemistry, 2007, 101, 1053-1059. | 2.1 | 237 |
| 54 | Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 466-478. | 1.5 | 236 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 55 | CSF Total tau, AÎ²42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease. Molecular Neurobiology, 2001, 24, 087-098. | 1.9 | 232 |
| 56 | Subjective cognitive decline and rates of incident Alzheimer's disease and nonâ€"Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476. | 0.4 | 232 |
| 57 | Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Annals of Neurology, 2001, 50, 150-156. | 2.8 | 229 |
| 58 | Bloodâ€based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer's and Dementia, 2017, 13, 45-58. | 0.4 | 227 |
| 59 | Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment. Brain, 2006, 129, 1113-1124. | 3.7 | 221 |
| 60 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328. | 1.3 | 215 |
| 61 | Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain, 2005, 128, 2626-2644. | 3.7 | 213 |
| 62 | Guidelines for the standardization of preanalytic variables for bloodâ€based biomarker studies in Alzheimer's disease research. Alzheimer's and Dementia, 2015, 11, 549-560. | 0.4 | 205 |
| 63 | A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Frontiers in Immunology, 2020, 11, 456. | 2.2 | 201 |
| 64 | White Matter Damage in Alzheimer Disease and Mild Cognitive Impairment: Assessment with Diffusion-Tensor MR Imaging and Parallel Imaging Techniques. Radiology, 2007, 243, 483-492. | 3.6 | 197 |
| 65 | Levels of Î²-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment. Archives of General Psychiatry, 2007, 64, 718. | 13.8 | 196 |
| 66 | The future of Alzheimer's disease: The next 10 years. Progress in Neurobiology, 2011, 95, 718-728. | 2.8 | 190 |
| 67 | Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. NeuroImage, 2007, 38, 13-24. | 2.1 | 185 |
| 68 | White matter microstructure underlying default mode network connectivity in the human brain. NeuroImage, 2010, 49, 2021-2032. | 2.1 | 185 |
| 69 | Corpus Callosum Atrophy Is a Possible Indicator of Regionâ€" and Cell Typeâ€"Specific Neuronal Degeneration in Alzheimer Disease. Archives of Neurology, 1998, 55, 193. | 4.9 | 178 |
| 70 | Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neuroscience Letters, 2000, 287, 187-190. | 1.0 | 176 |
| 71 | Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 474. | 0.4 | 176 |
| 72 | Subregional Basal Forebrain Atrophy in Alzheimer's Disease: A Multicenter Study. Journal of Alzheimer's Disease, 2014, 40, 687-700. | 1.2 | 173 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Reduced Hippocampal Volume in Healthy Young ApoE4 Carriers: An MRI Study. PLoS ONE, 2012, 7, e48895. | 1.1 | 168 |
| 74 | Progression of Corpus Callosum Atrophy in Alzheimer Disease. Archives of Neurology, 2002, 59, 243. | 4.9 | 167 |
| 75 | Tumor Necrosis Factor Death Receptor Signaling Cascade Is Required for Amyloid-Â Protein-Induced Neuron Death. Journal of Neuroscience, 2004, 24, 1760-1771. | 1.7 | 167 |
| 76 | Functional Connectivity Bias of the Orbitofrontal Cortex in Drug-Free Patients with Major Depression. Biological Psychiatry, 2010, 67, 161-167. | 0.7 | 164 |
| 77 | Multivariate network analysis of fiber tract integrity in Alzheimerâ€™s disease. NeuroImage, 2007, 34, 985-995. | 2.1 | 162 |
| 78 | The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125. | 0.4 | 162 |
| 79 | Cognitive and neuroimaging features and brain Î²-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurology, The, 2018, 17, 335-346. | 4.9 | 161 |
| 80 | Correlation of Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231 With Rates of Hippocampal Atrophy in Alzheimer Disease. Archives of Neurology, 2005, 62, 770. | 4.9 | 158 |
| 81 | Longitudinal Changes in Fiber Tract Integrity in Healthy Aging and Mild Cognitive Impairment: A DTI Follow-Up Study. Journal of Alzheimer's Disease, 2010, 22, 507-522. | 1.2 | 157 |
| 82 | Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Molecular Psychiatry, 2010, 15, 138-145. | 4.1 | 156 |
| 83 | Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661. | 1.1 | 155 |
| 84 | Exercise benefits on Alzheimerâ€™s disease: State-of-the-science. Ageing Research Reviews, 2020, 62, 101108. | 5.0 | 153 |
| 85 | Human antibodies against amyloid Î² peptide: A potential treatment for Alzheimer's disease. Annals of Neurology, 2002, 52, 253-256. | 2.8 | 152 |
| 86 | Relevance of Magnetic Resonance Imaging for Early Detection and Diagnosis of Alzheimer Disease. Medical Clinics of North America, 2013, 97, 399-424. | 1.1 | 151 |
| 87 | What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiology of Aging, 2020, 85, 58-73. | 1.5 | 150 |
| 88 | Cognitive intervention in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 508-517. | 4.9 | 149 |
| 89 | Cognitive and behavioural effects of physical exercise in psychiatric patients. Progress in Neurobiology, 2012, 96, 46-68. | 2.8 | 147 |
| 90 | Analytical performance and clinical utility of the INNOTESTÂ® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clinical Chemistry and Laboratory Medicine, 2006, 44, 1472-80. | 1.4 | 145 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 91 | Biological markers of amyloid β-related mechanisms in Alzheimer's disease. Experimental Neurology, 2010, 223, 334-346. | 2.0 | 145 |
| 92 | Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nature Reviews Neurology, 2021, 17, 580-589. | 4.9 | 144 |
| 93 | Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid. PLoS ONE, 2012, 7, e31501. | 1.1 | 143 |
| 94 | Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2015, 48, 403-410. | 1.2 | 138 |
| 95 | Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. Journal of Clinical Psychiatry, 2009, 70, 922-31. | 1.1 | 137 |
| 96 | The cholinergic system in mild cognitive impairment and Alzheimer's disease: An in vivo MRI and DTI study. Human Brain Mapping, 2011, 32, 1349-1362. | 1.9 | 136 |
| 97 | Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain, 2004, 127, 811-824. | 3.7 | 135 |
| 98 | REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMER'S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCH. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-14. | 1.5 | 135 |
| 99 | Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84. | 6.0 | 133 |
| 100 | Neuroanatomy of Down Syndrome in vivo: A Model of Preclinical Alzheimer's Disease. Behavior Genetics, 2006, 36, 405-415. | 1.4 | 131 |
| 101 | Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum. CNS Neuroscience and Therapeutics, 2009, 15, 358-374. | 1.9 | 129 |
| 102 | The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. Journal of Neurochemistry, 2006, 96, 635-644. | 2.1 | 123 |
| 103 | Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease, 2018, 64, S47-S105. | 1.2 | 122 |
| 104 | Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 764-775. | 0.4 | 122 |
| 105 | Effects of a Newly Developed Cognitive Intervention in Amnestic Mild Cognitive Impairment and mild Alzheimer's disease: A Pilot Study. Journal of Alzheimer's Disease, 2011, 25, 679-694. | 1.2 | 121 |
| 106 | Human anti-Â-amyloid antibodies block Â-amyloid fibril formation and prevent Â-amyloid-induced neurotoxicity. Brain, 2003, 126, 1935-1939. | 3.7 | 119 |
| 107 | Biomarkers for Alzheimer's disease therapeutic trials. Progress in Neurobiology, 2011, 95, 579-593. | 2.8 | 119 |
| 108 | Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Progress in Neurobiology, 2013, 101-102, 1-17. | 2.8 | 115 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 109 | Measurement of Î±- and Î²-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Experimental Neurology, 2003, 183, 74-80. | 2.0 | 114 |
| 110 | Age-related networks of regional covariance in MRI gray matter: Reproducible multivariate patterns in healthy aging. NeuroImage, 2010, 49, 1750-1759. | 2.1 | 113 |
| 111 | Blood-based biomarkers of microvascular pathology in Alzheimerâ€™s disease. Experimental Gerontology, 2010, 45, 75-79. | 1.2 | 112 |
| 112 | Development of biomarkers to chart all Alzheimer's disease stages: TheÂroyal road to cutting the therapeutic Gordian Knot. Alzheimer's and Dementia, 2012, 8, 312-336. | 0.4 | 112 |
| 113 | A Precision Medicine Initiative for Alzheimerâ€™s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric, 2017, 20, 107-118. | 1.1 | 112 |
| 114 | A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. Alzheimer's and Dementia, 2017, 13, 59-71. | 0.4 | 112 |
| 115 | Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. Psychophysiology, 2002, 39, 175-181. | 1.2 | 109 |
| 116 | Increased CSF-BACE 1 activity is associated with ApoE-Îµ4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain, 2008, 131, 1252-1258. | 3.7 | 109 |
| 117 | Assessing neuronal networks: Understanding Alzheimer's disease. Progress in Neurobiology, 2009, 89, 125-133. | 2.8 | 109 |
| 118 | Impact of employment status and work-related factors on risk of completed suicide. Psychiatry Research, 2011, 190, 265-270. | 1.7 | 109 |
| 119 | Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715. | 3.7 | 109 |
| 120 | Multiple Indices of Diffusion Identifies White Matter Damage in Mild Cognitive Impairment and Alzheimerâ€™s Disease. PLoS ONE, 2011, 6, e21745. | 1.1 | 108 |
| 121 | Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. Journal of Neurology, 2006, 253, 794-800. | 1.8 | 106 |
| 122 | Immunotherapy for Alzheimer's disease. Lancet Neurology, The, 2003, 2, 215-220. | 4.9 | 105 |
| 123 | Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochemical Pharmacology, 2014, 88, 426-449. | 2.0 | 105 |
| 124 | CSF biomarkers for the differential diagnosis of Alzheimer's disease: A largeâ€scale international multicenter study. Alzheimer's and Dementia, 2015, 11, 1306-1315. | 0.4 | 104 |
| 125 | Increased 3-Hydroxykynurenine serum concentrations differentiate Alzheimerâ€™s disease patients from controls. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 345-352. | 1.8 | 103 |
| 126 | International quality control survey of neurochemical dementia diagnostics. Neuroscience Letters, 2006, 409, 1-4. | 1.0 | 102 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 127 | Interhemispheric hypoconnectivity in schizophrenia: Fiber integrity and volume differences of the corpus callosum in patients and unaffected relatives. NeuroImage, 2012, 59, 926-934. | 2.1 | 102 |
| 128 | Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Annals of Neurology, 2001, 49, 545-546. | 2.8 | 99 |
| 129 | Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury. Brain, 2004, 127, 2629-2635. | 3.7 | 99 |
| 130 | Repetitive Transcranial Magnetic Stimulation (rTMS) in Major Depression Relation between Efficacy and Stimulation Intensity. Neuropsychopharmacology, 2002, 27, 638-45. | 2.8 | 98 |
| 131 | Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study. Psychiatry Research - Neuroimaging, 2011, 194, 363-371. | 0.9 | 98 |
| 132 | Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. Neuropsychology Review, 2017, 27, 245-257. | 2.5 | 97 |
| 133 | Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228. | 4.5 | 97 |
| 134 | Relation of Corpus Callosum and Hippocampal Size to Age in Nondemented Adults With Down's Syndrome. American Journal of Psychiatry, 2003, 160, 1870-1878. | 4.0 | 96 |
| 135 | Amyloid-$\beta$ Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 171-176. | 1.2 | 95 |
| 136 | Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiology of Aging, 2008, 29, 812-818. | 1.5 | 94 |
| 137 | Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophrenia Research, 1996, 19, 103-109. | 1.1 | 93 |
| 138 | Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A$\beta_{42}$ in patients with Alzheimer's disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 1-6. | 1.4 | 93 |
| 139 | Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychological Medicine, 2013, 43, 911-920. | 2.7 | 93 |
| 140 | Alzheimer's disease biomarker‐guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A$\beta_{1-42}$, total‐tau, phosphorylated‐tau, NFL, neurogranin, and YKL‐40. Alzheimer's and Dementia, 2018, 14, 492-501. | 0.4 | 91 |
| 141 | Discriminant power of combined cerebrospinal fluid I,, protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease1Preliminary parts of this study have been presented in abstract form at the 6th International Conference on Alzheimer's Disease and Related Disorders, July 18‐23, 1998, Amsterdam, The Netherlands and at the 28th Annual Meeting of the Society for Neuroscience, November 7‐12, 1998, Los Angeles, CA, USA.1. Brain Research, 1999, 823, 104-112. | 1.1 | 90 |
| 142 | Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 27, 404-417. | 0.7 | 90 |
| 143 | Robust Automated Detection of Microstructural White Matter Degeneration in Alzheimer's Disease Using Machine Learning Classification of Multicenter DTI Data. PLoS ONE, 2013, 8, e64925. | 1.1 | 89 |
| 144 | Altered Brain Activation During a Verbal Working Memory Task in Subjects with Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 103-118. | 1.2 | 86 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 145 | Anatomical MRI and DTI in the Diagnosis of Alzheimer's Disease: A European Multicenter Study. Journal of Alzheimer's Disease, 2012, 31, S33-S47. | 1.2 | 86 |
| 146 | Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. Neurobiology of Aging, 2013, 34, 2003-2013. | 1.5 | 86 |
| 147 | Regional networks underlying interhemispheric connectivity: An EEG and DTI study in healthy ageing and amnestic mild cognitive impairment. Human Brain Mapping, 2009, 30, 2098-2119. | 1.9 | 85 |
| 148 | Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183. | 6.0 | 85 |
| 149 | Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044. | 4.9 | 85 |
| 150 | White Matter Microstructure in Relation to Education in Aging and Alzheimer's Disease1. Journal of Alzheimer's Disease, 2009, 17, 571-583. | 1.2 | 84 |
| 151 | Differentiation of Geriatric Major Depression From Alzheimer's Disease With CSF Tau Protein Phosphorylated at Threonine 231. American Journal of Psychiatry, 2003, 160, 376-379. | 4.0 | 83 |
| 152 | Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. Biological Psychiatry, 2018, 83, 447-455. | 0.7 | 83 |
| 153 | ?-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Annals of Neurology, 2003, 54, 263-267. | 2.8 | 82 |
| 154 | Biomarker-based dissection of neurodegenerative diseases. Progress in Neurobiology, 2011, 95, 520-534. | 2.8 | 82 |
| 155 | Using Support Vector Machines with Multiple Indices of Diffusion for Automated Classification of Mild Cognitive Impairment. PLoS ONE, 2012, 7, e32441. | 1.1 | 80 |
| 156 | Novel MRI techniques in the assessment of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 58-69. | 3.3 | 79 |
| 157 | Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease. Molecular Neurodegeneration, 2010, 5, 2. | 4.4 | 79 |
| 158 | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. Scientific Reports, 2017, 7, 11706. | 1.6 | 79 |
| 159 | Precision pharmacology for Alzheimer's disease. Pharmacological Research, 2018, 130, 331-365. | 3.1 | 79 |
| 160 | Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. Alzheimer's and Dementia, 2018, 14, 1204-1215. | 0.4 | 79 |
| 161 | Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Expert Review of Proteomics, 2017, 14, 285-299. | 1.3 | 78 |
| 162 | CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis1Part of this work was presented in abstract form at the Twenty-Seventh Annual Meeting of the Society for Neuroscience, October 25–30, 1997, New Orleans, LA, USA.1. Journal of Neuroimmunology, 1999, 99, 218-223. | 1.1 | 75 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 163 | Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Aβ1–42 proteins to phosphorylated tau protein. Brain Research Bulletin, 2003, 61, 243-253. | 1.4 | 75 |
| 164 | Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiology of Aging, 2012, 33, 2272-2281. | 1.5 | 75 |
| 165 | Biomarkers in Sporadic and Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 291-317. | 1.2 | 75 |
| 166 | Free and Cued Selective Reminding Test – accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: A large‐scale biomarker‐characterized monocenter cohort study (ClinAD). Alzheimer's and Dementia, 2017, 13, 913-923. | 0.4 | 75 |
| 167 | The Alzheimer Precision Medicine Initiative. Journal of Alzheimer's Disease, 2019, 68, 1-24. | 1.2 | 75 |
| 168 | Regional network of magnetic resonance imaging gray matter volume in healthy aging. NeuroReport, 2006, 17, 951-956. | 0.6 | 74 |
| 169 | Fiber Connections between the Cerebral Cortex and the Corpus Callosum in Alzheimer's Disease: A Diffusion Tensor Imaging and Voxel-Based Morphometry Study. Cerebral Cortex, 2007, 17, 2276-2282. | 1.6 | 74 |
| 170 | Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Molecular Neurodegeneration, 2011, 6, 69. | 4.4 | 74 |
| 171 | Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. Ageing Research Reviews, 2021, 69, 101346. | 5.0 | 74 |
| 172 | Fractional Anisotropy Changes in Alzheimer's Disease Depend on the Underlying Fiber Tract Architecture: A Multiparametric DTI Study using Joint Independent Component Analysis. Journal of Alzheimer's Disease, 2014, 41, 69-83. | 1.2 | 71 |
| 173 | Frequency Variation of a Pattern-Flash Visual Stimulus during PET Differentially Activates Brain from Striate through Frontal Cortex. NeuroImage, 1997, 5, 116-128. | 2.1 | 70 |
| 174 | Oligoclonal Bands and Blood-Cerebrospinal-Fluid Barrier Dysfunction in a Subset of Patients with Alzheimer Disease: Comparison with Vascular Dementia, Major Depression, and Multiple Sclerosis. Alzheimer Disease and Associated Disorders, 1999, 13, 9-19. | 0.6 | 70 |
| 175 | Decreased serum amyloid β1–42 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide. Biological Psychiatry, 2005, 57, 813-816. | 0.7 | 70 |
| 176 | Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease. Neurobiology of Aging, 2006, 27, 10-15. | 1.5 | 69 |
| 177 | Galantamine for Alzheimer's disease. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 345-354. | 1.5 | 69 |
| 178 | Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. International Psychogeriatrics, 2008, 20, 67-76. | 0.6 | 68 |
| 179 | Staging Alzheimer's disease progression with multimodality neuroimaging. Progress in Neurobiology, 2011, 95, 535-546. | 2.8 | 68 |
| 180 | Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. Journal of Neural Transmission, 2012, 119, 39-52. | 1.4 | 68 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 181 | Functional Representation of Olfactory Impairment in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 581-591. | 1.2 | 66 |
| 182 | Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer's Disease. Neuropsychopharmacology, 2014, 39, 189-201. | 2.8 | 66 |
| 183 | Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease. Expert Review of Neurotherapeutics, 2017, 17, 47-57. | 1.4 | 65 |
| 184 | CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. , 2014, 10, 381-392. | | 64 |
| 185 | Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Review of Neurotherapeutics, 2015, 15, 83-105. | 1.4 | 64 |
| 186 | Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. Alzheimer's and Dementia, 2021, 17, 1528-1553. | 0.4 | 64 |
| 187 | Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Neuroscience Letters, 1997, 228, 143-146. | 1.0 | 63 |
| 188 | Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nature Reviews Drug Discovery, 2013, 12, 324-324. | 21.5 | 63 |
| 189 | Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. Neuroscience Letters, 1999, 277, 21-24. | 1.0 | 62 |
| 190 | Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology, 2006, 187, 86-94. | 1.5 | 62 |
| 191 | Prevention trials in Alzheimer's disease: An EU-US task force report. Progress in Neurobiology, 2011, 95, 594-600. | 2.8 | 62 |
| 192 | Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clinical Chemistry and Laboratory Medicine, 2011, 49, 367-374. | 1.4 | 62 |
| 193 | Identification of Novel Biomarker Candidates by Differential Peptidomics Analysis of Cerebrospinal Fluid in Alzheimers Disease. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 801-806. | 0.6 | 61 |
| 194 | Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 8-12. | 0.6 | 61 |
| 195 | Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Experimental Gerontology, 2009, 44, 579-585. | 1.2 | 60 |
| 196 | Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 269-278. | 1.8 | 59 |
| 197 | Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2-Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia <scp>A</scp>lzheimer's Disease Study. Journal of the American Geriatrics Society, 2011, 59, 2273-2281. | 1.3 | 59 |
| 198 | Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. Alzheimer's and Dementia, 2017, 13, 454-467. | 0.4 | 58 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 199 | Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924. | 0.4 | 58 |
| 200 | EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN PRIMARY CARE. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-6. | 1.5 | 58 |
| 201 | Assessing Therapeutic Efficacy in a Progressive Disease. CNS Drugs, 2006, 20, 311-325. | 2.7 | 57 |
| 202 | microRNA-Based Biomarkers in Alzheimer's Disease (AD). Frontiers in Neuroscience, 2020, 14, 585432. | 1.4 | 57 |
| 203 | Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neuroscience Letters, 1999, 259, 145-148. | 1.0 | 56 |
| 204 | The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. International Journal of Psychophysiology, 2000, 37, 87-98. | 0.5 | 56 |
| 205 | Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Review of Molecular Diagnostics, 2010, 10, 667-690. | 1.5 | 56 |
| 206 | Association between white matter fiber integrity and subclinical psychotic symptoms in schizophrenia patients and unaffected relatives. Schizophrenia Research, 2012, 140, 129-135. | 1.1 | 56 |
| 207 | Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747. | 2.8 | 56 |
| 208 | Blood-Cerebrospinal Fluid Barrier Dysfunction for High Molecular Weight Proteins in Alzheimer Disease and Major Depression. Alzheimer Disease and Associated Disorders, 1997, 11, 78-87. | 0.6 | 55 |
| 209 | No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain, 2007, 130, e82-e82. | 3.7 | 55 |
| 210 | Total and Phosphorylated Tau Proteins: Evaluation as Core Biomarker Candidates in Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2004, 17, 350-354. | 0.7 | 54 |
| 211 | Validation of AclarusDx™, a Blood-Based Transcriptomic Signature for the Diagnosis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 169-181. | 1.2 | 54 |
| 212 | Interleukin-6–174 G/C Promoter Gene Polymorphism C Allele Reduces Alzheimer's Disease Risk. Journal of the American Geriatrics Society, 2003, 51, 578-579. | 1.3 | 53 |
| 213 | Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 127-137. | 1.8 | 53 |
| 214 | Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease. Progress in Neurobiology, 2011, 95, 557-569. | 2.8 | 53 |
| 215 | The Role of Variation at AβPP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 377-387. | 1.2 | 53 |
| 216 | Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease. Brain Research, 1998, 780, 356-359. | 1.1 | 52 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 217 | Region-Specific Corpus Callosum Atrophy Correlates With the Regional Pattern of Cortical Glucose Metabolism in Alzheimer Disease. Archives of Neurology, 1999, 56, 467. | 4.9 | 52 |
| 218 | Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neuroscience Letters, 2003, 339, 172-174. | 1.0 | 52 |
| 219 | Biomarkers in the Diagnosis of Alzheimer's Disease: Are We Ready?. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 172-179. | 1.2 | 52 |
| 220 | Functional abnormalities of the visual processing system in subjects with mild cognitive impairment: An fMRI study. Psychiatry Research - Neuroimaging, 2008, 163, 248-259. | 0.9 | 52 |
| 221 | Diagnostic Usefulness of Cognitive Auditory Event-Related P300 Subcomponents in Patients With Alzheimers Disease?. Journal of Clinical Neurophysiology, 2008, 25, 147-152. | 0.9 | 52 |
| 222 | Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1599-1608. | 1.5 | 52 |
| 223 | Different Effects of Mirtazapine and Venlafaxine on Brain Activation. Journal of Clinical Psychiatry, 2011, 72, 448-457. | 1.1 | 52 |
| 224 | Increased CSF-BACE1 Activity Associated with Decreased Hippocampus Volume in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 25, 373-381. | 1.2 | 50 |
| 225 | Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of Aging, 2019, 83, 42-53. | 1.5 | 48 |
| 226 | THE ROAD AHEAD TO CURE ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS. journal of prevention of Alzheimer's disease, The, 2014, 1, 1-22. | 1.5 | 48 |
| 227 | Long-Term Observation of a Multicomponent Cognitive Intervention in Mild Cognitive Impairment. Journal of Clinical Psychiatry, 2012, 73, e1492-e1498. | 1.1 | 48 |
| 228 | Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease. Journal of the Neurological Sciences, 2002, 194, 15-19. | 0.3 | 47 |
| 229 | Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study. Brain, 2007, 130, 1745-1758. | 3.7 | 47 |
| 230 | Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. Psychiatry Research - Neuroimaging, 2010, 182, 244-250. | 0.9 | 46 |
| 231 | Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. Neurochemistry International, 2017, 108, 355-360. | 1.9 | 46 |
| 232 | Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification. Frontiers in Neuroendocrinology, 2018, 50, 31-51. | 2.5 | 46 |
| 233 | Effects of a 6-Month Cognitive Intervention on Brain Metabolism in Patients with Amnestic MCI and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 337-348. | 1.2 | 45 |
| 234 | Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. Annals of Nuclear Medicine, 2018, 32, 75-86. | 1.2 | 45 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 235 | Association of cerebrospinal fluid α-synuclein with total and phospho-tau$_{181}$ protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2018, 14, 1623-1631. | 0.4 | 45 |
| 236 | Alzheimer Disease: Functional Abnormalities in the Dorsal Visual Pathway. Radiology, 2010, 254, 219-226. | 3.6 | 44 |
| 237 | Amyloid-β and Cognition in Aging and Alzheimer's Disease: Molecular and Neurophysiological Mechanisms. Journal of Alzheimer's Disease, 2012, 33, S79-S86. | 1.2 | 44 |
| 238 | Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 27-34. | 1.2 | 44 |
| 239 | Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. Journal of Alzheimer's Disease, 2019, 69, 615-629. | 1.2 | 44 |
| 240 | Pisa Syndrome (Pleurothotonus). Journal of Clinical Psychiatry, 2000, 61, 569-574. | 1.1 | 44 |
| 241 | Biological and methodical challenges of blood-based proteomics in the field of neurological research. Progress in Neurobiology, 2013, 101-102, 18-34. | 2.8 | 43 |
| 242 | Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research and Therapy, 2017, 9, 101. | 3.0 | 43 |
| 243 | Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 940-950. | 0.4 | 43 |
| 244 | Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamine-induced neurotoxicity. Life Sciences, 2006, 79, 1307-1311. | 2.0 | 42 |
| 245 | The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. Expert Review of Molecular Diagnostics, 2020, 20, 421-441. | 1.5 | 42 |
| 246 | Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. Dementia and Geriatric Cognitive Disorders, 2013, 36, 1-19. | 0.7 | 41 |
| 247 | Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. PLoS ONE, 2014, 9, e100812. | 1.1 | 41 |
| 248 | The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. Expert Review of Proteomics, 2019, 16, 593-600. | 1.3 | 41 |
| 249 | FDG-PET mapping the brain substrates of visuo-constructive processing in Alzheimer´s disease. Journal of Psychiatric Research, 2010, 44, 462-469. | 1.5 | 40 |
| 250 | Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention. Progress in Neurobiology, 2011, 95, 491-495. | 2.8 | 40 |
| 251 | Cortical–basal ganglia imbalance in schizophrenia patients and unaffected first-degree relatives. Schizophrenia Research, 2012, 138, 120-127. | 1.1 | 40 |
| 252 | The rising global tide of cognitive impairment. Nature Reviews Neurology, 2016, 12, 131-132. | 4.9 | 40 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 253 | The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. , 2008, 4, 255-264. | | 39 |
| 254 | Blood-Based Microcirculation Markers in Alzheimer's Diseaseâ€"Diagnostic Value of Midregional Pro-atrial Natriuretic Peptide/C-terminal Endothelin-1 Precursor Fragment Ratio. Biological Psychiatry, 2009, 65, 979-984. | 0.7 | 39 |
| 255 | Biomarkers for major depression and its delineation from neurodegenerative disorders. Progress in Neurobiology, 2011, 95, 703-717. | 2.8 | 39 |
| 256 | Twoâ€level diagnostic classification using cerebrospinal fluid YKLâ€40 in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 993-1003. | 0.4 | 39 |
| 257 | Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues in Clinical Neuroscience, 2009, 11, 141-157. | 1.8 | 39 |
| 258 | Alzheimer's disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology. Journal of Nutrition, Health and Aging, 2012, 16, 339-345. | 1.5 | 38 |
| 259 | Time for the systems-level integration of aging: Resilience enhancing strategies to prevent Alzheimerâ€™s disease. Progress in Neurobiology, 2019, 181, 101662. | 2.8 | 38 |
| 260 | EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTING. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-8. | 1.5 | 38 |
| 261 | Serotonin transporter (5-HTT) gene polymorphism in psychogeriatric patients. Neuroscience Letters, 2000, 284, 113-115. | 1.0 | 37 |
| 262 | Subjective memory complaints in community dwelling healthy older people: the influence of brain and psychopathology. International Journal of Geriatric Psychiatry, 2012, 27, 836-843. | 1.3 | 37 |
| 263 | RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIES. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-7. | 1.5 | 37 |
| 264 | Toward noninvasive brain stimulation 2.0 in Alzheimerâ€™s disease. Ageing Research Reviews, 2022, 75, 101555. | 5.0 | 37 |
| 265 | From inherited to sporadic ADâ€"crossing the biomarker bridge. Nature Reviews Neurology, 2012, 8, 598-600. | 4.9 | 36 |
| 266 | Association of microstructural white matter abnormalities with cognitive dysfunction in geriatric patients with major depression. Psychiatry Research - Neuroimaging, 2012, 203, 194-200. | 0.9 | 36 |
| 267 | Systems Biology Methods for Alzheimerâ€™s Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials. Methods in Molecular Biology, 2018, 1750, 31-66. | 0.4 | 36 |
| 268 | REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMERâ€™S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMERâ€™S DISEASE TASK FORCE. journal of prevention of Alzheimer's disease, The, 2016, 3, 1-7. | 1.5 | 36 |
| 269 | Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 753-762. | 1.2 | 36 |
| 270 | Decreased Activation Along the Dorsal Visual Pathway After a 3-Month Treatment With Galantamine in Mild Alzheimer Disease. Journal of Clinical Psychopharmacology, 2009, 29, 147-156. | 0.7 | 35 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 271 | Treatment Options for Tauopathies. Current Treatment Options in Neurology, 2012, 14, 126-136. | 0.7 | 35 |
| 272 | Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2017, 59, 1327-1334. | 1.2 | 35 |
| 273 | Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. Frontiers in Pharmacology, 2019, 10, 310. | 1.6 | 35 |
| 274 | Early risk assessment for Alzheimer's disease. Alzheimer's and Dementia, 2009, 5, 182-196. | 0.4 | 34 |
| 275 | Neural adaptation to thin and fat bodies in the fusiform body area and middle occipital gyrus: An fMRI adaptation study. Human Brain Mapping, 2013, 34, 3233-3246. | 1.9 | 34 |
| 276 | Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S171-S191. | 1.2 | 34 |
| 277 | Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease. Trends in Neurosciences, 2017, 40, 469-480. | 4.2 | 34 |
| 278 | Using Diffusion Tensor Imaging and Mixed-Effects Models to Investigate Primary and Secondary White Matter Degeneration in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2011, 26, 667-682. | 1.2 | 33 |
| 279 | The European DTI Study on Dementia — A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. NeuroImage, 2017, 144, 305-308. | 2.1 | 33 |
| 280 | Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. Neurobiology of Aging, 2019, 77, 112-127. | 1.5 | 33 |
| 281 | Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. Molecular Neurobiology, 2020, 57, 4667-4691. | 1.9 | 33 |
| 282 | State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 159-177. | 0.4 | 33 |
| 283 | Imaging Epigenetics in Alzheimer's Disease. Current Pharmaceutical Design, 2013, 19, 6393-6415. | 0.9 | 33 |
| 284 | Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors. Frontiers in Neurology, 2018, 9, 642. | 1.1 | 32 |
| 285 | Prefrontal Cortex Modulation of Mood and Emotionally Induced Facial Expressions. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 206-212. | 0.9 | 31 |
| 286 | Reliable manual segmentation of the frontal, parietal, temporal, and occipital lobes on magnetic resonance images of healthy subjects. Brain Research Protocols, 2005, 14, 135-145. | 1.7 | 31 |
| 287 | Diagnostic Utility of Novel MRI-Based Biomarkers for Alzheimer's Disease: Diffusion Tensor Imaging and Deformation-Based Morphometry. Journal of Alzheimer's Disease, 2010, 20, 477-490. | 1.2 | 31 |
| 288 | Common capacity-limited neural mechanisms of selective attention and spatial working memory encoding. European Journal of Neuroscience, 2011, 34, 827-838. | 1.2 | 31 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 289 | Disrupted white matter structural networks in healthy older adult APOE Îµ4 carriers â€" An international multicenter DTI study. Neuroscience, 2017, 357, 119-133. | 1.1 | 31 |
| 290 | A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2â€73) Phase 2a clinical study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12013. | 1.8 | 31 |
| 291 | Successful aging: insights from proteome analyses of healthy centenarians. Aging, 2020, 12, 3502-3515. | 1.4 | 31 |
| 292 | A multicenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe. European Radiology, 2006, 16, 1096-1103. | 2.3 | 30 |
| 293 | Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Progress in Neurobiology, 2011, 95, 547-556. | 2.8 | 30 |
| 294 | Effects of a 6-Month Cognitive Intervention Program on Brain Metabolism in Amnestic Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 25, 695-706. | 1.2 | 30 |
| 295 | Revised criteria for Alzheimer's disease: what are the lessons for clinicians?. Lancet Neurology, The, 2011, 10, 598-601. | 4.9 | 30 |
| 296 | Longitudinal changes of fractional anisotropy in Alzheimerâ€™s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 341-350. | 1.8 | 30 |
| 297 | Cerebrospinal fluid analysis in Alzheimerâ€™s disease: technical issues and future developments. Journal of Neurology, 2014, 261, 1234-1243. | 1.8 | 30 |
| 298 | CSF biomarkers for Alzheimerâ€™s pathology and the effect size of APOE É›4. Molecular Psychiatry, 2014, 19, 148-149. | 4.1 | 30 |
| 299 | Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimerâ€™s Disease. Methods in Molecular Biology, 2016, 1303, 49-67. | 0.4 | 30 |
| 300 | Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid-Î² Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. Radiology, 2019, 290, 167-176. | 3.6 | 30 |
| 301 | Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis. Statistical Methods in Medical Research, 2020, 29, 151-164. | 0.7 | 30 |
| 302 | Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. Neurobiology of Aging, 2020, 90, 43-59. | 1.5 | 30 |
| 303 | Biomarkers in clinical trials for neurodegenerative diseases: Regulatory perspectives and requirements. Progress in Neurobiology, 2011, 95, 498-500. | 2.8 | 29 |
| 304 | Fully Automated Atlas-Based Hippocampal Volumetry for Detection of Alzheimer's Disease in a Memory Clinic Setting. Journal of Alzheimer's Disease, 2015, 44, 183-193. | 1.2 | 29 |
| 305 | Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience, 2018, 10, 67. | 1.7 | 29 |
| 306 | High-resolution peptide mapping of cerebrospinal fluid: a novel concept for diagnosis and research in central nervous system diseases. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 782, 353-361. | 1.2 | 28 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 307 | Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 44-48. | 1.8 | 28 |
| 308 | Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 330-336. | 1.8 | 28 |
| 309 | Discovery and development of integrative biological markers for schizophrenia. Progress in Neurobiology, 2011, 95, 686-702. | 2.8 | 28 |
| 310 | Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. Journal of Nutrition, Health and Aging, 2013, 17, 54-63. | 1.5 | 28 |
| 311 | Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. Journal of Alzheimer's Disease, 2015, 48, 793-804. | 1.2 | 28 |
| 312 | The phenotypical core of Alzheimer's disease–related and nonrelated variants of the corticobasal syndrome: A systematic clinical, neuropsychological, imaging, and biomarker study. Alzheimer's and Dementia, 2016, 12, 786-795. | 0.4 | 28 |
| 313 | Increased levels of CSF phosphorylated tau in apolipoprotein E ɛ4 carriers with mild cognitive impairment. Neuroscience Letters, 2005, 391, 48-50. | 1.0 | 27 |
| 314 | Ethical considerations of biomarker use in neurodegenerative diseases—A case study of Alzheimer's disease. Progress in Neurobiology, 2011, 95, 517-519. | 2.8 | 27 |
| 315 | Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognitive Impairment. Current Alzheimer Research, 2011, 8, 893-901. | 0.7 | 27 |
| 316 | The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40. | 1.5 | 27 |
| 317 | Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology, 2021, 185, 108081. | 2.0 | 27 |
| 318 | CSF tau and β-amyloid as biomarkers for mild cognitive impairment. Dialogues in Clinical Neuroscience, 2004, 6, 379-390. | 1.8 | 27 |
| 319 | The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. Psychiatry Research - Neuroimaging, 2010, 183, 44-51. | 0.9 | 26 |
| 320 | CALHM1 P86L Polymorphism Modulates CSF Aβ Levels in Cognitively Healthy Individuals at Risk for Alzheimer's Disease. Molecular Medicine, 2011, 17, 974-979. | 1.9 | 26 |
| 321 | Increased Plasma TACE Activity in Subjects with Mild Cognitive Impairment and Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 877-886. | 1.2 | 26 |
| 322 | DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive–compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 87-106. | 1.8 | 26 |
| 323 | Sexual Dimorphism in Healthy Aging and Mild Cognitive Impairment: A DTI Study. PLoS ONE, 2012, 7, e37021. | 1.1 | 26 |
| 324 | Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases. Molecular Diagnosis and Therapy, 2011, 15, 83-102. | 1.6 | 25 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 325 | The Îµ4 genotype of apolipoprotein E and white matter integrity in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 401-404. | 0.4 | 25 |
| 326 | Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort. Journal of Alzheimer's Disease, 2015, 46, 199-209. | 1.2 | 25 |
| 327 | Brain AÎ² load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. Alzheimer's and Dementia, 2019, 15, 1274-1285. | 0.4 | 25 |
| 328 | Prediction of Alzheimerâ€™s Disease Using Midregional Proadrenomedullin and Midregional Proatrial Natriuretic Peptide. Journal of Clinical Psychiatry, 2011, 72, 556-563. | 1.1 | 25 |
| 329 | Evidence of Blood-Cerebrospinal Fluid-Barrier Impairment in a Subgroup of Patients with Dementia of the Alzheimer Type and Major Depression: A Possible Indicator for Immunoactivation. Dementia and Geriatric Cognitive Disorders, 1995, 6, 348-354. | 0.7 | 24 |
| 330 | Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment. Biological Psychiatry, 2011, 70, 145-151. | 0.7 | 24 |
| 331 | The role of genetics for biomarker development in neurodegeneration. Progress in Neurobiology, 2011, 95, 501-504. | 2.8 | 24 |
| 332 | Human Anti-prion Antibodies Block Prion Peptide Fibril Formation and Neurotoxicity. Journal of Biological Chemistry, 2012, 287, 12858-12866. | 1.6 | 24 |
| 333 | Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention. International Psychogeriatrics, 2012, 24, S10-S17. | 0.6 | 24 |
| 334 | Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. Neurobiology of Aging, 2020, 91, 88-111. | 1.5 | 24 |
| 335 | The Latent Dementia Phenotype Î´ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 49, 547-560. | 1.2 | 23 |
| 336 | DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequencesâ€"part 1: general aspects and paradigmatic discussion of depressive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 5-18. | 1.8 | 23 |
| 337 | Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. Neuropharmacology, 2016, 108, 128-135. | 2.0 | 23 |
| 338 | Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. Alzheimer's Research and Therapy, 2020, 12, 147. | 3.0 | 23 |
| 339 | Relation between responses to repetitive transcranial magnetic stimulation and partial sleep deprivation in major depression. Journal of Psychiatric Research, 2002, 36, 131-135. | 1.5 | 22 |
| 340 | Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease. Progress in Neurobiology, 2011, 95, 570-578. | 2.8 | 22 |
| 341 | Alzheimer disease: From biomarkers to diagnosis. Revue Neurologique, 2013, 169, 744-751. | 0.6 | 22 |
| 342 | Predicting Progression from Cognitive Impairment to Alzheimerâ€™s Disease with the Disease State Index. Current Alzheimer Research, 2015, 12, 69-79. | 0.7 | 22 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 343 | Biomarker-guided classification scheme of neurodegenerative diseases. Journal of Sport and Health Science, 2016, 5, 383-387. | 3.3 | 22 |
| 344 | Preclinical effects of APOE Îµ4 on cerebrospinal fluid AÎ²42 concentrations. Alzheimer's Research and Therapy, 2017, 9, 87. | 3.0 | 22 |
| 345 | Perspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S329-S347. | 1.2 | 21 |
| 346 | InÂvivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. Neurobiology of Aging, 2020, 93, 98-108. | 1.5 | 21 |
| 347 | Optimal management of Alzheimer&amp;rsquo;s disease patients: Clinical guidelines and family advice. Neuropsychiatric Disease and Treatment, 2010, 6, 243. | 1.0 | 20 |
| 348 | Mechanical stress related to brain atrophy in Alzheimer's disease. , 2016, 12, 11-20. | | 20 |
| 349 | Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment. Neurobiology of Aging, 2017, 55, 177-189. | 1.5 | 20 |
| 350 | Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHTâ€preAD study. Alzheimer's and Dementia, 2018, 14, 1126-1136. | 0.4 | 20 |
| 351 | Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology, 2020, 94, e30-e41. | 1.5 | 20 |
| 352 | Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimerâ€™s Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 51, 867-873. | 1.2 | 19 |
| 353 | No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. NeuroImage: Clinical, 2018, 17, 435-443. | 1.4 | 19 |
| 354 | Accuracy of MRI Classification Algorithms in a Tertiary Memory Center Clinical Routine Cohort. Journal of Alzheimer's Disease, 2020, 74, 1157-1166. | 1.2 | 19 |
| 355 | White Matter Differences between Healthy Young ApoE4 Carriers and Non-Carriers Identified with Tractography and Support Vector Machines. PLoS ONE, 2012, 7, e36024. | 1.1 | 19 |
| 356 | Expression of T Cell [Receptor Î³Î´ Antigens in Human Brain Tissue. NeuroImmunoModulation, 1995, 2, 115-120. | 0.9 | 18 |
| 357 | Regional Differences in Effects of &lt;i&gt;APOE&lt;/i&gt; Îµ4 on Cognitive Impairment in Non-Demented Subjects. Dementia and Geriatric Cognitive Disorders, 2011, 32, 135-142. | 0.7 | 18 |
| 358 | Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimerâ€™s Disease and Other Neurodegenerative Disorders. NeuroMolecular Medicine, 2017, 19, 154-160. | 1.8 | 18 |
| 359 | Association of plasma YKL-40 with brain amyloid-Î² levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32. | 1.5 | 18 |
| 360 | Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints. Neurobiology of Aging, 2017, 57, 143-152. | 1.5 | 18 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 361 | The temporal localization of frame-shift ubiquitin-B and amyloid precursor protein, and complement proteins in the brain of non-demented control patients with increasing Alzheimer's disease pathology. Neuroscience Letters, 2003, 348, 46-50. | 1.0 | 17 |
| 362 | Tau in cerebrospinal fluid: A sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification. Neuroscience Letters, 2007, 418, 186-189. | 1.0 | 17 |
| 363 | Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. Dialogues in Clinical Neuroscience, 2019, 21, 177-191. | 1.8 | 17 |
| 364 | Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation. Journal of Neuroimmunology, 2010, 221, 62-67. | 1.1 | 16 |
| 365 | Stage-Dependent Agreement between Cerebrospinal Fluid Proteins and FDG-PET Findings in Alzheimer's Disease. Current Alzheimer Research, 2012, 9, 241-247. | 0.7 | 16 |
| 366 | Î²-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. Alzheimer's Research and Therapy, 2020, 12, 130. | 3.0 | 16 |
| 367 | The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. Expert Review of Proteomics, 2020, 17, 543-559. | 1.3 | 16 |
| 368 | A Case of Ganser's State Presenting as a Dementia Syndrome. Psychopathology, 1996, 29, 236-241. | 1.1 | 15 |
| 369 | Alzheimer's disease, depression and normal ageing: merit of simple psychomotor and visuospatial tasks. , 2000, 15, 31-39. | | 15 |
| 370 | Corpus Callosum Measurement as an in Vivo Indicator for Neocortical Neuronal Integrity, but not White Matter Pathology, in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2000, 903, 470-476. | 1.8 | 15 |
| 371 | Response to Boban et al: computer-assisted 3D reconstruction of the nucleus basalis complex, including the nucleus subputaminalis (Ayala's nucleus). Brain, 2006, 129, E43-E43. | 3.7 | 15 |
| 372 | Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation. Journal of Neuroimmunology, 2007, 189, 169-174. | 1.1 | 15 |
| 373 | Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. Journal of Personalized Medicine, 2020, 10, 138. | 1.1 | 15 |
| 374 | Polymorphisms in the apolipoprotein E (APOE) gene in gerontopsychiatric patients. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 24-28. | 1.8 | 14 |
| 375 | Anticonvulsants in the treatment of aggression in the demented elderly: an update. Clinical Practice and Epidemiology in Mental Health, 2009, 5, 14. | 0.6 | 14 |
| 376 | Patterns of Autobiographical Memory in Bipolar Disorder Examined by Psychometric and Functional Neuroimaging Methods. Journal of Nervous and Mental Disease, 2012, 200, 296-304. | 0.5 | 14 |
| 377 | Evolving Relevance of Neuroproteomics in Alzheimer's Disease. Methods in Molecular Biology, 2017, 1598, 101-115. | 0.4 | 14 |
| 378 | Genetic Association of <i>CDC2</i> with Cerebrospinal Fluid Tau in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 20, 367-374. | 0.7 | 13 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 379 | Pharmacological treatment of Alzheimer's dementia: State of the art and current dilemmas. World Journal of Biological Psychiatry, 2008, 9, 69-75. | 1.3 | 13 |
| 380 | APOE-Dependent Phenotypes in Subjects with Mild Cognitive Impairment Converting to Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 37, 389-401. | 1.2 | 13 |
| 381 | MiRNA-15b and miRNA-125b are associated with regional AÎ²-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. Translational Psychiatry, 2021, 11, 78. | 2.4 | 13 |
| 382 | Polymorphisms in the Î±-2 macroglobulin gene in psychogeriatric patients. Neuroscience Letters, 2000, 294, 69-72. | 1.0 | 12 |
| 383 | A frontline defense against neurodegenerative diseases:the development of early disease detection methods. Expert Review of Molecular Diagnostics, 2019, 19, 559-563. | 1.5 | 12 |
| 384 | Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. Methods in Molecular Biology, 2018, 1750, 139-155. | 0.4 | 12 |
| 385 | Translations of Measurements and Scales: Opportunities and Diversities. International Psychogeriatrics, 2000, 12, 391-394. | 0.6 | 11 |
| 386 | Blood-based diagnostics of Alzheimerâ€™s disease. Expert Review of Molecular Diagnostics, 2019, 19, 613-621. | 1.5 | 11 |
| 387 | Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. Clinical Neurophysiology, 2020, 131, 2716-2731. | 0.7 | 11 |
| 388 | No association between anti-myelin oligodendrocyte glycoprotein antibodies and serum/cerebrospinal fluid levels of the soluble interleukin-6 receptor complex in multiple sclerosis. Neuroscience Letters, 2001, 305, 13-16. | 1.0 | 10 |
| 389 | Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective. Journal of Nutrition, Health and Aging, 2012, 16, 346-348. | 1.5 | 10 |
| 390 | Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study. Psychiatry Research - Neuroimaging, 2016, 249, 84-90. | 0.9 | 10 |
| 391 | Improved Cerebrospinal Fluid-Based Discrimination between Alzheimerâ€™s Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555. | 1.2 | 10 |
| 392 | Plasma Î²â€secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. Alzheimer's and Dementia, 2021, 17, 629-640. | 0.4 | 10 |
| 393 | Association of Î²-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra. Neurology, 2022, 98, . | 1.5 | 10 |
| 394 | A New Sandwich Immunoassay for Detection of the Î±-Secretase Cleaved, Soluble Amyloid-Î² Protein Precursor in Cerebrospinal Fluid and Serum. Journal of Alzheimer's Disease, 2013, 37, 667-678. | 1.2 | 9 |
| 395 | Combination of Structural MRI andÂFDG-PET of the Brain Improves Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric Inpatients. Journal of Alzheimer's Disease, 2016, 54, 1319-1331. | 1.2 | 9 |
| 396 | EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. Neurobiology of Aging, 2021, 103, 78-97. | 1.5 | 9 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 397 | Detection of the Novel CeID Adhesion Molecule MUC18 Human Brain Tissue. NeuroImmunoModulation, 1997, 4, 57-61. | 0.9 | 8 |
| 398 | Melanoma-Associated Adhesion Molecule MUC18/MCAM (CD146) and Transcriptional Regulator Mader in Normal Human CNS. NeuroImmunoModulation, 1998, 5, 270-276. | 0.9 | 8 |
| 399 | Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes. World Journal of Biological Psychiatry, 2011, 12, 109-113. | 1.3 | 8 |
| 400 | Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice. PLoS ONE, 2018, 13, e0190212. | 1.1 | 8 |
| 401 | Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. Expert Review of Proteomics, 2021, 18, 27-48. | 1.3 | 8 |
| 402 | COGNITIVE REHABILITATION IN ALZHEIMER'S DISEASE – A CONCEPTUAL AND METHODOLOGICAL REVIEW. journal of prevention of Alzheimer's disease, The, 2015, 2, 1-11. | 1.5 | 8 |
| 403 | The Association Between APOE Îµ4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of Alzheimer's Disease, 2013, 35, 241-246. | 1.2 | 7 |
| 404 | Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer's Disease. Current Pharmaceutical Design, 2013, 19, 6416-6425. | 0.9 | 7 |
| 405 | Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 151-164. | 1.2 | 7 |
| 406 | THE SARS-COV-2 PANDEMIC AND THE BRAVE NEW DIGITAL WORLD OF ENVIRONMENTAL ENRICHMENT TO PREVENT BRAIN AGING AND COGNITIVE DECLINE. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-5. | 1.5 | 7 |
| 407 | Evaluation of major national dementia policies and health‐care system preparedness for early medical action and implementation. Alzheimer's and Dementia, 2022, 18, 1993-2002. | 0.4 | 7 |
| 408 | Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study. Aging Clinical and Experimental Research, 2020, 32, 817-826. | 1.4 | 6 |
| 409 | Physiology and biochemistry of the interleukin-6 receptor complex: Implications for CNS disorders and Alzheimer's disease. , 2001, , 121-143. | | 6 |
| 410 | Targets of Antidementive Therapy: Drugs with a Specific Pharmacological Mechanism of Action. Current Pharmaceutical Design, 2004, 10, 223-229. | 0.9 | 6 |
| 411 | Unstable Anticoagulation in the Course of Amitriptyline Treatment. Pharmacopsychiatry, 1996, 29, 33-37. | 1.7 | 5 |
| 412 | TURNING POINT TOWARDS BLOOD BIOMARKER-GUIDED TARGETED THERAPY FOR PRECISION MEDICINE IN ALZHEIMER'S DISEASE. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-5. | 1.5 | 5 |
| 413 | Aptamarker prediction of brain amyloid-Î² status in cognitively normal individuals at risk for Alzheimer's disease. PLoS ONE, 2021, 16, e0243902. | 1.1 | 5 |
| 414 | Association of plasma AÎ²40/AÎ²42 ratio and brain AÎ² accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. Neurobiology of Aging, 2021, 107, 57-69. | 1.5 | 5 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 415 | A review of the reversible MAO-A inhibitor moclobemide in geriatric patients. Human Psychopharmacology, 1998, 13, 43-51. | 0.7 | 4 |
| 416 | Perspectives of worldwide translational biomarker research in neurodegenerative diseases. Progress in Neurobiology, 2011, 95, 496-497. | 2.8 | 4 |
| 417 | Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?. Alzheimer's Research and Therapy, 2013, 5, 11. | 3.0 | 4 |
| 418 | Magnetic resonance imagingâ€'based hippocampus volume for prediction of dementia in mild cognitive impairment: Why does the measurement method matter so little?. Alzheimer's and Dementia, 2018, 14, 976-978. | 0.4 | 4 |
| 419 | Association of brain network dynamics with plasma biomarkers in subjective memory complainers. Neurobiology of Aging, 2020, 88, 83-90. | 1.5 | 4 |
| 420 | Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimerâ€™s and other neurodegenerative diseases. Expert Review of Neurotherapeutics, 2021, 21, 949-967. | 1.4 | 4 |
| 421 | E.U./U.S. CTAD TASK FORCE ON ALZHEIMER'S TRIAL POPULATIONS. journal of prevention of Alzheimer's disease, The, 2014, 1, 1-7. | 1.5 | 4 |
| 422 | Î±-synuclein as an emerging pathophysiological biomarker of Alzheimerâ€™s disease. Expert Review of Molecular Diagnostics, 2022, 22, 411-425. | 1.5 | 4 |
| 423 | Modified Oral Anticoagulant Potency in an Amitriptyline-Treated Patient?. Acta Haematologica, 1996, 96, 178-180. | 0.7 | 3 |
| 424 | COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMERâ€™S DISEASE LIQUID BIOPSY. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-3. | 1.5 | 3 |
| 425 | Expression of Human Heat-Shock Protein 70 Antigens and ?/? T-Cell Receptor Antigens in Human Central Nervous Tissue. Annals of the New York Academy of Sciences, 1994, 741, 305-315. | 1.8 | 3 |
| 426 | Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis. Frontiers in Aging Neuroscience, 2021, 13, 748198. | 1.7 | 3 |
| 427 | CNS demyelination in monoclonal gammopathy of undetermined significance (MGUS): possible cause of a dementia syndrome. European Psychiatry, 1996, 11, 46-49. | 0.1 | 2 |
| 428 | P2-212 Age-related cortical grey matter reductions in nondemented down's syndrome adults determined by magnetic resonance imaging with voxel-based morphometry. Neurobiology of Aging, 2004, 25, S290. | 1.5 | 2 |
| 429 | Frontal diaschisis in a German case of fatal familial insomnia. Journal of Neurology, 2006, 253, 1510-1512. | 1.8 | 2 |
| 430 | Standardization of MRI and Amyloid Imaging. , 2014, , 131-156. | | 2 |
| 431 | Alzheimerâ€™s Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. Journal of Alzheimer's Disease, 2017, 60, 577-583. | 1.2 | 2 |
| 432 | Aging and sex impact plasma NFL and tâ€'Tau trajectories in individuals at risk for Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e041792. | 0.4 | 2 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 433 | Psychodrug-induced and EDTA associated thrombocytopenia: important factors in the differential diagnosis of low platelet counts. European Psychiatry, 1996, 11, 416-418. | 0.1 | 1 |
| 434 | Case Report/Case Series: Severe Hirsutism associated with Psychopharmacoiogical Treatment in Major Depression. World Journal of Biological Psychiatry, 2001, 2, 48-49. | 1.3 | 1 |
| 435 | The problem of being a paradigm: the emergence of neural stem cells as example for â€œKuhnianâ€• revolution in biology or misconception of the scientific community?. Poiesis & Praxis, 2009, 6, 3-11. | 0.3 | 1 |
| 436 | P2-192: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA. , 2014, 10, P541-P542. | | 1 |
| 437 | P3â€218: NOVEL ALZHEIMER'S DISEASE BIOMARKERâ€GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: Aβ$_{1â€42}$, TOTALâ€TAU, PHOSPHORYLATEDâ€TAU, NFL, NEUROGRANIN, AND YKLâ€40. Alzheimer's and Dementia, 2018, 14, P1154. | 0.4 | 1 |
| 438 | P1â€431: APOEâ€DEPENDENT LONGITUDINAL CHANGES IN DEFAULT MODE NETWORK FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P474. | 0.4 | 1 |
| 439 | Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Annals of Neurology, 2001, 49, 545-546. | 2.8 | 1 |
| 440 | 19 MRI as a Surrogate Marker in Clinical Trials in Alzheimerâ€™s Disease. , 2009, , 305-318. | | 1 |
| 441 | Biological Mechanism-based Neurology and Psychiatry: a BACE1/2 and Downstream Pathway Model. Current Neuropharmacology, 2021, 19, . | 1.4 | 1 |
| 442 | Diagnostic Tools: Fluid Biomarkers for AlzheimerÂ's Disease. Advances in Biological Psychiatry, 2012, , 71-79. | 0.2 | 0 |
| 443 | MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimerâ€™s Disease. Advances in Biological Psychiatry, 2012, , 80-114. | 0.2 | 0 |
| 444 | S3-01-02: SCREENING FOR AD: WHY AND HOW?. , 2014, 10, P200-P200. | | 0 |
| 445 | IC-P-067: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA. , 2014, 10, P37-P37. | | 0 |
| 446 | [ICâ€Pâ€152]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTINGâ€STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHTâ€PRE AD STUDY. Alzheimer's and Dementia, 2017, 13, P114. | 0.4 | 0 |
| 447 | [P1â€"388]: DIFFERENT STRUCTURAL CONNECTIVITY PATTERNS IN MILD COGNITIVE IMPAIRMENT STRATIFIED BY AMYLOID AND NEURODEGENERATION BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P414. | 0.4 | 0 |
| 448 | [P1â€"441]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTINGâ€STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHTâ€PREâ€AD STUDY. Alzheimer's and Dementia, 2017, 13, P451. | 0.4 | 0 |
| 449 | P4â€072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL. Alzheimer's and Dementia, 2018, 14, P1461. | 0.4 | 0 |
| 450 | P1â€627: AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PREâ€AD COHORT. Alzheimer's and Dementia, 2018, 14, P581. | 0.4 | 0 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 451 | P3â€411: CLINICAL SIGNIFICANCE OF INâ€VIVO STAGING OF REGIONAL AMYLOID DEPOSITION IN SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P1262. | 0.4 | 0 |
| 452 | P2â€237: ASSOCIATION OF CSF ALPHAâ€SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P762. | 0.4 | 0 |
| 453 | P3â€248: STRATIFICATION OF INDIVIDUALS FOR PET AMYLOID POSITIVITY AND ALZHEIMER'S DISEASE RISK USING POLYGENIC RISK SCORE ANALYSIS: NEW OPPORTUNITIES FOR CLINICAL TRIAL DESIGN. Alzheimer's and Dementia, 2018, 14, P1168. | 0.4 | 0 |
| 454 | P4â€027: EVIDENCE FOR COGNITIVE COMPENSATION IN EARLY AMYLOIDOSIS IN HIGHâ€PERFORMING HEALTHY ELDERLY AT RISK FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1443. | 0.4 | 0 |
| 455 | O4â€07â€04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN. Alzheimer's and Dementia, 2018, 14, P1419. | 0.4 | 0 |
| 456 | O3â€09â€02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOIDâ€PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P1036. | 0.4 | 0 |
| 457 | P4â€098: ASSOCIATION BETWEEN COGNITIVE RESERVE AND WHITE MATTER MICROSTRUCTURAL INTEGRITY IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P1474. | 0.4 | 0 |
| 458 | P2â€397: REDUCED BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO MEN. Alzheimer's and Dementia, 2018, 14, P855. | 0.4 | 0 |
| 459 | P2â€246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKLâ€40 CONCENTRATIONS IN AMYLOIDâ€PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P767. | 0.4 | 0 |
| 460 | P2â€249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P768. | 0.4 | 0 |
| 461 | P2â€355: CORRELATION OF FUNCTIONAL MRI CONNECTOMES WITH PATHOPHYSIOLOGICAL ALZHEIMER'S PLASMA BIOMARKERS AND RISK FACTORS IN SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P824. | 0.4 | 0 |
| 462 | Reply: Optimal use of cholinergic drugs in Alzheimerâ€™s disease. Brain, 2018, 141, e69. | 3.7 | 0 |
| 463 | Association of plasma YKLâ€40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e041753. | 0.4 | 0 |
| 464 | Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e046014. | 0.4 | 0 |
| 465 | Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e046105. | 0.4 | 0 |
| 466 | Locus coeruleus assessment by MRI: A comparison of three different approaches. Journal of the Neurological Sciences, 2021, 429, 118309. | 0.3 | 0 |
| 467 | Diagnostik und Therapie demenzieller Syndrome (ICD-10 F0). , 2012, , 1-20. | | 0 |
| 468 | Diagnostik und Therapie demenzieller Syndrome (ICD-10 F0). , 2013, , 1-24. | | 0 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 469 | Aktuelle MÃ¶glichkeiten und Perspektiven der Liquoruntersuchung bei der Alzheimer Demenz. , 1999, , 153-166. | | 0 |
| 470 | MRI-based imaging of Alzheimerâ€™s disease. , 2015, , 199-213. | | 0 |
| 471 | Education and brain amyloid load act on temporal lobe function in individual with subjective memory complaint: An EEGâ€fMRI study. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |